Hugo Salguero, MD
Pain Medicine · Tulsa, OKNPI 1578643383
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,596 of the $10,251 with a category attached, or 74.1%. 39 manufacturers reported payments, led by Nevro Corp. at 30.9% of the total.
Across 384 payments — averaging $26.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$3K
- Si-bone, Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$730
- Collegium Pharmaceutical, Inc.$699
- AbbVie$548
- Medtronic$489
- plus $3K from 33 others
What the payments were for
- Travel & lodging$2,65626%
- Food & beverage$7,59674%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 29 | $3,168 |
| Si-bone, Inc. | 12 | $1,269 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 54 | $730 |
| Collegium Pharmaceutical, Inc. | 42 | $699 |
| AbbVie(2 entities) | 34 | $548 |
| Medtronic(2 entities) | 29 | $489 |
| Saluda Medical Americas, Inc. | 6 | $465 |
| Forte Bio-pharma LLC | 33 | $432 |
| Boston Scientific | 10 | $365 |
| Arbor Pharmaceuticals, Inc. | 20 | $341 |
| Scilex Pharmaceuticals Inc. | 14 | $237 |
| Pfizer | 16 | $160 |
| Averitas Pharma Inc. | 9 | $160 |
| Daiichi Sankyo Inc. | 10 | $155 |
| Biodelivery Sciences International, Inc. | 14 | $152 |
| Amgen(2 entities) | 9 | $137 |
| MML US, Inc. | 1 | $75 |
| Novartis | 3 | $70 |
| Abbott | 3 | $52 |
| Kowa Pharmaceuticals America, Inc. | 3 | $48 |
| GRT US Holding, Inc. | 4 | $48 |
| Lilly USA, LLC | 4 | $47 |
| AstraZeneca | 2 | $37 |
| Pacira Therapeutics, Inc. | 2 | $37 |
| Valinor Pharma, LLC | 2 | $37 |
| Zyla Life Sciences, Inc. | 3 | $35 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Vertex | 1 | $29 |
| Zimmer Biomet | 2 | $28 |
| Bioventus LLC | 1 | $26 |
| Almatica Pharma LLC | 2 | $25 |
| Lundbeck LLC | 1 | $21 |
| Johnson & Johnson | 1 | $17 |
| MDD US Operations, LLC | 1 | $15 |
| Appliedvr Inc | 1 | $14 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Tonix Medicines, Inc. | 1 | $14 |
| Assertio Therapeutics, Inc. | 1 | $13 |
| IBSA Pharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,251 in reported general payments places this provider in the 75th percentile of 68 pain medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 3,194 | $94,482 |
| BelbucaBuprenorphine Hcl | 104 | $74,518 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 2,127 | $71,187 |
| Xtampza ErOxycodone Myristate | 169 | $55,997 |
| QutenzaCapsaicin/Skin Cleanser | 13 | $46,575 |
| Buprenorphine | 151 | $30,498 |
| OxycontinOxycodone Hcl | 60 | $19,104 |
| Fentanyl | 127 | $14,209 |
| Morphine Sulfate ErMorphine Sulfate | 742 | $13,238 |
| Hysingla ErHydrocodone Bitartrate | 32 | $10,550 |
| MovantikNaloxegol Oxalate | 18 | $8,975 |
| Morphine Sulfate | 300 | $7,432 |
| Oxycodone Hcl | 363 | $5,604 |
| Pregabalin | 303 | $5,359 |
| ButransBuprenorphine | 12 | $4,527 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $699 | $130,515273 claims |
| GRT US Holding, Inc.Qutenza | $48 | $46,57513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 68 pain medicine providers in Oklahoma.
Other pain medicine in Tulsa
- Brian TorgersonTulsa$13K
- Lam NguyenTulsa$11K
- Jayen PatelTulsa$10K
- Adam WallaceTulsa$8K
- Kenneth ReedTulsa$7K
- Ahmad KhattabTulsa$7K
- David DoTulsa$6K
- Emad Attallah-WasifTulsa$4K
- Leslie ChanTulsa$4K
- Chancen HallTulsa$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.